These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 10819459)

  • 1. Pretreatment platelet 5-HT concentration predicts the short-term response to paroxetine in major depression.
    Goodnick PJ; Kumar AM
    Biol Psychiatry; 2000 May; 47(9):846-7. PubMed ID: 10819459
    [No Abstract]   [Full Text] [Related]  

  • 2. Pretreatment platelet 5-HT concentration predicts the short-term response to paroxetine in major depression. Grupo de Trastornos Afectivos.
    Figueras G; Pérez V; San Martino O; Alvarez E; Artigas F
    Biol Psychiatry; 1999 Aug; 46(4):518-24. PubMed ID: 10459402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paroxetine: a review of clinical experience.
    Dunner D; Kumar R
    Pharmacopsychiatry; 1998 May; 31(3):89-101. PubMed ID: 9657236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dopaminergic sensitivity and prediction of antidepressant response.
    Healy E; McKeon P
    J Psychopharmacol; 2000 Jun; 14(2):152-6. PubMed ID: 10890309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paroxetine/bupropion combination treatment for refractory depression.
    Marshall RD; Liebowitz MR
    J Clin Psychopharmacol; 1996 Feb; 16(1):80-1. PubMed ID: 8834426
    [No Abstract]   [Full Text] [Related]  

  • 6. Successful paroxetine treatment of major depression in an adult form of metachromatic leukodystrophy with cognitive disturbances.
    Vella G; Loriedo C; Raccah R; Baldassarre P; Paolillo A
    Can J Psychiatry; 1998 Sep; 43(7):748-9. PubMed ID: 9773228
    [No Abstract]   [Full Text] [Related]  

  • 7. Withdrawal after discontinuation of paroxetine.
    Arya DK
    Aust N Z J Psychiatry; 1996 Oct; 30(5):702. PubMed ID: 8902183
    [No Abstract]   [Full Text] [Related]  

  • 8. Resolution of treatment-refractory depression with naltrexone augmentation of paroxetine--a case report.
    Amiaz R; Stein O; Dannon PN; Grunhaus L; Schreiber S
    Psychopharmacology (Berl); 1999 Apr; 143(4):433-4. PubMed ID: 10367562
    [No Abstract]   [Full Text] [Related]  

  • 9. Olanzapine in the treatment of resistant depression.
    Caetano D; Caetano SC
    Aust N Z J Psychiatry; 2005; 39(1-2):108-9. PubMed ID: 15660713
    [No Abstract]   [Full Text] [Related]  

  • 10. Economics of treatment of depression.
    Owens DW
    Br J Psychiatry; 1995 Jul; 167(1):112. PubMed ID: 7551591
    [No Abstract]   [Full Text] [Related]  

  • 11. Relationship between parameters of serotonin transport and antidepressant plasma levels or therapeutic response in depressive patients treated with paroxetine and amitriptyline.
    Kuhs H; Schlake HP; Rolf LH; Rudolf GA
    Acta Psychiatr Scand; 1992 May; 85(5):364-9. PubMed ID: 1534961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exacerbation of extrapyramidal symptoms with paroxetine.
    Arya DK; McKenzie J; Worrall N
    Aust N Z J Psychiatry; 1995 Sep; 29(3):521-2. PubMed ID: 8573063
    [No Abstract]   [Full Text] [Related]  

  • 13. Paroxetine for the prevention of depression induced by interferon alfa.
    Kraus MR; Schäfer A; Scheurlen M
    N Engl J Med; 2001 Aug; 345(5):375-6. PubMed ID: 11484704
    [No Abstract]   [Full Text] [Related]  

  • 14. Plasma free 3-methoxy-4-hydroxyphenylglycol predicts response to fluoxetine.
    Ko HC; Lu RB; Shiah IS; Hwang CC
    Biol Psychiatry; 1997 Apr; 41(7):774-81. PubMed ID: 9084896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological treatment of depression: the role of paroxetine.
    Deahl M
    Hosp Med; 2001 Jan; 62(1):38-42. PubMed ID: 11211460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost analysis of paroxetine versus imipramine in major depression.
    Bentkover JD; Feighner JP
    Pharmacoeconomics; 1995 Sep; 8(3):223-32. PubMed ID: 10155618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paroxetine treatment of depression in late life.
    Reynolds CF
    Psychopharmacol Bull; 2003; 37 Suppl 1():123-34. PubMed ID: 14566207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can serotonin and fluoxetine levels in plasma and platelets predict clinical response in depression?
    Castrogiovanni P; Blardi P; De Lalla A; Dell'Erba A; Auteri A
    Psychopharmacol Bull; 2003; 37(2):102-8. PubMed ID: 14566218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversible hepatotoxicity of paroxetine in a patient with major depression.
    Helmchen C; Boerner RJ; Meyendorf R; Hegerl U
    Pharmacopsychiatry; 1996 Nov; 29(6):223-6. PubMed ID: 8956353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lithium addition in antidepressant-resistant depression: effects on platelet 5-HT, plasma 5-HT and plasma 5-HIAA concentration.
    Birkenhäger TK; van den Broek WW; Fekkes D; Mulder PG; Moleman P; Bruijn JA
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1084-8. PubMed ID: 17467132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.